Can You Take Olanzapine with Escitalopram?
A plain-English look at the moderate interaction between Olanzapine (APO-Olanzapine ODT) and Escitalopram (Lexapro) — what it means, why it happens, and what to talk to your doctor or pharmacist about.
Combining Olanzapine (APO-Olanzapine ODT) with Escitalopram (Lexapro) is a moderate interaction requiring caution and monitoring. Risk of serotonin syndrome, especially with tramadol and tapentadol combined with SSRIs/SNRIs. Additive CNS depression with sedating antidepressants.
Not sure about your specific combination? Check it in the Drug Interaction Checker →
Key Takeaways
- Interaction severity: Moderate
- Risk: Serotonin syndrome (agitation, hyperthermia, rigidity), excessive sedation.
- Mechanism: Risk of serotonin syndrome, especially with tramadol and tapentadol combined with SSRIs/SNRIs. Additive CNS depression with sedating antidepressants.
- Olanzapine: S4 in Australia, moderate risk
- Escitalopram: S4 in Australia, low risk
- Claims action: Monitor and document. Request clinical justification if combination is ongoing.
Olanzapine vs Escitalopram at a Glance
| Property | Olanzapine | Escitalopram |
|---|---|---|
| Brand names | APO-Olanzapine ODT, Olanzapine Sandoz ODT 5, PRYZEX ODT | Lexapro, Lexam 10, Cilopam-S |
| Drug class | opioid | antidepressant |
| Risk level | moderate | low |
| TGA Schedule (AU) | S4 | S4 |
Why Is This Combination Dangerous?
Risk of serotonin syndrome, especially with tramadol and tapentadol combined with SSRIs/SNRIs. Additive CNS depression with sedating antidepressants.
Regulatory Guidance by Jurisdiction
Australia TGA / SIRA / WorkSafe
The TGA and Australian Medicines Handbook classify this as a moderate drug interaction requiring monitoring and clinical review.
United Kingdom NICE / MHRA / FPM
NICE guidelines advise against combining multiple serotonergic medications due to the risk of serotonin syndrome. For personal injury claims, antidepressant prescribing should be reviewed for injury relatedness and appropriateness.
United States FDA / CDC / State WC
The FDA has issued Drug Safety Communications about the risk of serotonin syndrome with concurrent use of serotonergic medications. Workers compensation nurse case managers should flag this combination for prescriber review.
What Claims Professionals Should Do
- Document the combination in the claim file with a note on interaction risk
- Request clinical justification from the prescriber at the next review
- Monitor for adverse effects including excessive sedation, falls, and cognitive impairment
- Assess injury relatedness of both medications to the compensable condition
- Review at next claim assessment and consider whether the combination is still clinically appropriate
Clinical reference
A clinical summary of Olanzapine and Escitalopram drawn from regulator advisories, national guidelines, and authoritative drug references. Read this if you want the deeper clinical picture before talking to your prescriber or pharmacist.
Severity assessment
Moderate. The primary concern is an increased risk of QT interval prolongation, which can lead to serious and potentially life-threatening heart rhythm abnormalities.
Mechanism (plain English)
Both escitalopram and olanzapine can affect the electrical activity of the heart, specifically prolonging the QT interval. The QT interval represents the time it takes for the heart's ventricles to depolarize and repolarize. When this interval is prolonged, it can lead to a type of irregular heartbeat called Torsade de Pointes, which can be fatal. Escitalopram, a selective serotonin reuptake inhibitor (SSRI), can cause a dose-dependent QT prolongation. Olanzapine, an atypical antipsychotic, has also been associated with QT prolongation, though its clinical significance is less certain and often attributed to confounding factors. When these two medications are used together, their individual effects on the QT interval can be additive, increasing the overall risk.
Evidence level
Guideline-supported. The interaction is noted in clinical drug interaction databases and product information, with recommendations for caution and monitoring due to the potential for QT prolongation.
Top regulator advisories (cite verbatim or close paraphrase)
- TGA (Australia): No specific public advisory found for the escitalopram + olanzapine pair. However, the Product Information for escitalopram (e.g., Escitalopram Sandoz) generally advises caution with concomitant use of other drugs that prolong the QT interval. [TGA ARTG 290456]
- MHRA / NICE (UK): No specific guidance found for this exact pair. However, the MHRA has previously issued drug safety updates regarding citalopram and escitalopram and their potential for QT interval prolongation, advising that details of specific interactions can be found in individual Summaries of Product Characteristics. [MHRA Drug Safety Update, 2014]
- FDA / CDC (US): The FDA label for escitalopram (Lexapro) lists QT prolongation as a postmarketing adverse event and contraindicates its use with pimozide due to increased risk of QT prolongation and/or ventricular arrhythmias. The label also advises caution with other serotonergic drugs due to the risk of serotonin syndrome, and drugs that affect hemostasis due to increased bleeding risk. The olanzapine (Zyprexa) FDA label states that it is uncertain whether olanzapine causes clinically significant prolongation of the QT interval, but advises caution with CNS-acting drugs. [FDA Lexapro Label, 2023; FDA Zyprexa Label, 2014]
- EMA (Europe): No specific public advisory found for the escitalopram + olanzapine pair. Product information for escitalopram generally advises caution with other QT-prolonging drugs.
Clinical risk factors that elevate the danger
- Pre-existing cardiac conditions: Patients with a history of cardiac arrhythmias, congenital long QT syndrome, or other heart diseases are at higher risk.
- Electrolyte imbalances: Conditions like hypokalemia (low potassium) or hypomagnesemia (low magnesium), often due to severe or prolonged diarrhea or vomiting, can increase the risk of QT prolongation.
- Concomitant use of other QT-prolonging drugs: Using other medications known to prolong the QT interval alongside escitalopram and olanzapine further increases the risk.
- Higher doses: Increased doses of either escitalopram or olanzapine may increase the risk of QT prolongation.
- Hepatic impairment: Patients with liver problems may have reduced clearance of these medications, leading to higher drug levels and increased risk.
What a patient should be told
- Taking escitalopram and olanzapine together can increase the risk of a rare but serious heart problem called QT prolongation, which can lead to an irregular heartbeat. It's important to be aware of this risk.
- Do not stop taking either medication suddenly without talking to your doctor or pharmacist first. Suddenly stopping can cause other serious side effects.
- Watch out for warning signs of a heart problem, such as feeling dizzy, lightheaded, faint, having a fast or irregular heartbeat (palpitations), or shortness of breath. If you experience any of these, seek medical attention immediately.
- Discuss with your doctor or pharmacist if there are safer alternative medications or if your current treatment plan needs adjustment, especially if you have a heart condition or other health issues.
- If you experience severe dizziness, fainting, or a very fast or irregular heartbeat, seek urgent medical care right away.
Top 3 sources (with full citation)
- Escitalopram and Olanzapine Interactions. Drugs.com. Available at: https://www.drugs.com/drug-interactions/escitalopram-with-olanzapine-1013-0-1744-0.html?professional=1
- Lexapro (escitalopram) FDA Prescribing Information. U.S. Food and Drug Administration. Revised 5/2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021323s055,021365s039lbl.pdf
- Zyprexa (olanzapine) FDA Prescribing Information. U.S. Food and Drug Administration. Revised 2014. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020592s062021086s040021253s048lbl.pdf
Notes for the reviewing pharmacist
The interaction between escitalopram and olanzapine regarding QT prolongation is primarily an additive pharmacodynamic effect. While escitalopram is clearly associated with dose-dependent QT prolongation, the contribution of olanzapine is less definitively established in clinical trials, with some sources noting uncertainty and confounding factors in isolated case reports. The FDA label for olanzapine does not explicitly list escitalopram as a drug interaction for QT prolongation, but advises caution with other CNS-acting drugs. The risk is heightened in patients with pre-existing cardiac conditions or electrolyte imbalances. Monitoring for ECG changes and clinical symptoms of Torsade de Pointes is crucial, especially during initiation or dose adjustments. It is important to educate patients on warning signs without causing undue alarm, emphasizing open communication with healthcare providers. The lack of specific pair-wise advisories from some regulators (e.g., TGA, MHRA, EMA) highlights the need to rely on general class warnings and individual drug product information for risk assessment. This interaction is not a formal contraindication but warrants careful clinical judgment and patient-specific risk assessment.
Sources used in this brief (3)
Check this medication against your full medication list
Check all interactions for Olanzapine and Escitalopram across your claimant's full medication list.
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile in minutes. Free for individuals; team plans for case managers, insurers, and schemes.
Related Resources
Important: This page is general health information, not personal medical advice. If you have questions about your medication — including starting it, stopping it, changing the dose, or combining it with something else — speak with your doctor or pharmacist. For an emergency or suspected overdose, call your local emergency number or poison information service immediately. Information is drawn from regulator and clinical guideline sources (TGA, FDA, MHRA, NICE, PBS, CDC); see our methodology for details.